Lipocine (Lipocine) Retained Earnings : $-196.26 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lipocine Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Lipocine's retained earnings for the quarter that ended in Mar. 2024 was $-196.26 Mil.

Lipocine's quarterly retained earnings declined from Sep. 2023 ($-197.50 Mil) to Dec. 2023 ($-199.78 Mil) but then increased from Dec. 2023 ($-199.78 Mil) to Mar. 2024 ($-196.26 Mil).

Lipocine's annual retained earnings declined from Dec. 2021 ($-172.67 Mil) to Dec. 2022 ($-183.43 Mil) and declined from Dec. 2022 ($-183.43 Mil) to Dec. 2023 ($-199.78 Mil).

Lipocine Retained Earnings Historical Data

The historical data trend for Lipocine's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Retained Earnings Chart

Lipocine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-151.07

-172.03

-172.67

-183.43

-199.78

Lipocine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-187.30	-190.84	-197.50	-199.78	-196.26

Lipocine Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Lipocine (NAS:LPCN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Lipocine (Lipocine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108

Website

http://www.lipocine.com

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Executives

Mahesh V. Patel	director, officer: President and CEO	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono	director	18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos	director	C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos	officer: Chief Medical Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty	officer: Principal Accounting Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi	director	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown	officer: EVP and CFO	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink	director	2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass	officer: EVP and Chief Commercial Offic	3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila	officer: Chief Business Officer	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran	officer: CTO and VP RandD	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell	officer: VP Finance	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons	officer: VP Corp Business Development	837 4TH AVE, SALT LAKE CITY UT 84103